Abstract 444P
Background
High-dose cytarabine (HDAC) is used to treat hematologic malignancies. Eye disorders are common side effects caused by cytarabine (AraC) being transported from the blood into tear fluid. In our institution, four times a day (FM4) or six times a day (FM6) of 0.1% fluorometholone eye drops are used to prevent AraC-induced eye disorders. In this study, we investigated the prophylactic effects of FM6 or FM4 to prevent AraC-induced eye disorders retrospectively.
Methods
We targeted the patients who were hospitalized and administered with HDAC twice a day at a dose of 1 g/m2 or more between April 2011 and March 2018. The patients received 0.1% fluorometholone eye drops in a both eyes from the start of HDAC dose to 48 hours after the end of HDAC dose. We investigated the incidence of eye disorders or grade based on the medical records from the start of HDAC dose until 7 days after the end of HDAC dose, retrospectively.
Results
There were 36 patients of FM4 and 44 of FM6 for prevention of AraC-induced eye disorders, respectivity. The incidence of eye disorders was 6 (16.7%) in FM4 and 7 (15.9%) in FM6. No Grade 3 eye disorders occurred in both groups. The number of courses of the eye disorder appeared for FM4 and FM6 were 1 and 2 courses. In addition, the median of AraC cumulative dose at the time of the eye disorders appeared for FM4 and FM6 was 10 (4-20) g/m2 and 20 (6-42) g/m2.
Conclusions
There is no difference in preventive effect between FM4 and FM6 for AraC-induced eye disorders. Further, FM4 is considered useful and a convenient method for the prevention of AraC-induced eye disorders.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract